

XXXIII CONGRESSO NAZIONALE AIRO

AIRO2023

BOLOGNA,
27-29 OTTOBRE 2023

PALAZZO DEI CONGRESSI

Radioterapia Oncologica: l'evoluzione al servizio dei pazienti

Intelligenza Artificiale, come cambierà il futuro delle nostre discipline: SIRM, AIMN, AIRO

Il punto di vista del radioterapista oncologo

Valerio Nardone

Dipartimento di Medicina di Precisione, AOU Vanvitelli, Napoli

Disclosures


Per quanto concerne tale presentazione, dichiaro di non avere avuto alcuna relazione rilevante (diretta od indiretta) di tipo finanziario con alcuna compagnia farmaceutica negli ultimi 24 mesi che possa essere considerato un **conflitto di interesse**.



Outline

➤ *Definition;*

- *Application in RadOnc;*
- *New application (ESTRO, ASTRO);*
- *Reaction of our community*
- *Is there a future for #RadOnc with AI?*



In computer science, *artificial intelligence* (AI), is intelligence demonstrated by machines, in contrast to the *natural intelligence* displayed by humans and animals. The term AI is used to describe machines that mimic *cognitive* functions associated with human minds, such as *learning* and *problem solving*.



AIRO2023

Other terms

- *Machine learning*: it is an application of AI that provides systems the ability to automatically learn and improve from experience without explicit programming;
- *Neural Networks*: are computing systems inspired by the biological neural networks and nodes called artificial neurons.
- *Data mining*: is the practice of examining large databases to generate new informations;

Radioterapia Oncologica:
l'evoluzione al servizio dei pazienti



Automatic Recognition of Ripening Tomatoes by artificial intelligence

Artificial Intelligence in Factories



Japan ranked fourth in the world: In 2016, 303 robots were installed per 10,000 employees in the manufacturing industry.

AI in Health

Timeline of AI in health

1980s-1990s
1955

Term coined by John McCarthy. Founded as an academic discipline in 1956 in US.


Growth of microcomputer and new levels of network connectivity. AI systems in healthcare was designed to accommodate the absence of perfect data and build on the expertise of physicians.

2019 & onwards

- Discovery and development of drugs
- Preclinical research
- Personalized Health Care
- And many more

2010-2019
1960-1970

Produced first problem-solving program, or expert system, known as Dendral assisting to identifying bacteria and recommending antibiotics



Special Reports > Exclusives

AI Passes U.S. Medical Licensing Exam


— Two papers show that large language models, including ChatGPT, can pass the USMLE

by [Michael DePeau-Wilson](#), Enterprise & Investigative Writer, MedPage Today January 19, 2023



BRAIN DECODING: TOWARD REAL-TIME RECONSTRUCTION OF VISUAL PERCEPTION


Yohann Benchetrit^{1,*}, Hubert Banville^{1,*}, Jean-Rémi King^{1,2}
¹FAIR, Meta, ²Laboratoire des Systèmes Perceptifs, École Normale Supérieure, PSL University
{ybenchetrit,hubertjb,jeanremi}@meta.com



Sam Altman



Mark Zuckerberg



Viewed Image

Predicted Image



Giuliano Amato

Jurist, politician, former minister now newly elected president of the AI algorithms commission, just wanted by the government. Among the objectives is the study of the applications of AI in the publishing world.

85 years old.



Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography

Peter G. Mikhael, BSc^{1,2}; Jeremy Wohlwend, ME^{1,2}; Adam Yala, PhD^{1,2}; Ludvig Karstens, MSc^{1,2}; Justin Xiang, ME^{1,2}; Angelo K. Takigami, MD^{3,4}; Patrick P. Bourgooin, MD^{3,4}; PuiYee Chan, PhD⁵; Sofiane Mrah, MSc⁴; Wael Amayri, BSc⁴; Yu-Hsiang Juan, MD^{6,7}; Cheng-Ta Yang, MD^{6,8}; Yung-Liang Wan, MD^{6,7}; Gigin Lin, MD, PhD^{6,7}; Lecia V. Sequist, MD, MPH^{3,5}; Florian J. Fintelmann, MD^{3,4}; and Regina Barzilay, PhD^{1,2}




FIG 2. Receiver operating characteristic curves displaying Sybil's ability to predict future lung cancer over 6 years following a single low-dose computed tomography from the (A) NLST, (B) MGH, and (C) CGMH test sets. CIs for each curve can be found in [Table 1](#). AUC, area under the curve; C-index, concordance index; CGMH, Chang Gung Memorial Hospital; MGH, Massachusetts General Hospital; NLST, National Lung Screening Trial.

Journal of Clinical Oncology®

Volume 41, Issue 12 2191






FIG 3. Examples of screening scans with negative clinical interpretations (Lung-RADS 1 or 2) and high Sybil risk scores, who subsequently developed lung cancer. Paired sets of images from four separate subjects from the National Lung Screening Trial and Massachusetts General Hospital cohorts illustrating Sybil's potential in predicting future lung cancer. Clinical (preoperative) or pathologic (postoperative) stages are provided using

Outline

- *Definition;*
- *Application in RadOnc;*
- *New application (ESTRO, ASTRO);*
- *Reaction of our community*
- *Is there a future for #RadOnc with AI?*





AI in Radiation Oncology






Huynh et al. Nat Rev Clin Oncol 2020

The Emergence of Artificial Intelligence within Radiation Oncology Treatment Planning, Tetherton et al. Oncology 2021



Hype cycle. This figure features a hype cycle curve for three major innovations in radiation oncology (triangle: Monte Carlo; square: Inverse optimization/IMRT; circle: deep learning-based contouring). The curve depicts expectations by the target audience (those in radiation oncology and medical physics) as a function of time. Yellow, magenta, cyan, green, and blue portions of the curve denote “innovation trigger,” “peak of inflated expectations,” “trough of disillusionment,” “slope of enlightenment,” and “productivity plateau” regions, respectively.

Use of AI in 2020




Supplemental Table 1. Number of Radiation Oncology Departments using or preparing to use machine learning applications in clinical practice per country

Radiation Oncology Departments and Machine Learning Applications		
	Clinical	Preparing
France	8	5
Italy	7	3
Netherlands	8	3
Spain	7	2
Australia	5	4
Belgium	5	3
United Kingdom	4	3
Denmark	3	2
Switzerland	3	3
United States of Amerika	3	1
Germany	2	2
Norway	2	3

C.L. Brouwer et al. Physics and Imaging in Radiation Oncology 2020

Outline

- *Definition;*
- *Application in RadOnc;*
- *New application (ESTRO, ASTRO);*
- *Reaction of our community*
- *Is there a future for #RadOnc with AI?*



AI: friend or foe

AI is a friend

- Time reduction for the radiotherapist (contours, planning),
- Improve accuracy and precision in RT treatments,
- Predict toxicity,
- Cost reduction.

AI is a foe

- “ I may take your job ” ,
- Incorrect treatment decisions with incomplete or biased data,
- Manipulation of AI algorithms or steal patient data by hackers.

ESTRO2022 09:15 Artificial intelligence: Friend or foe of the RTT? 10:30 Chairperson: Michelle Leech Auditorium 12

Learning from Every Patient

ESTRO 2022

6-10 May 2022
ONSITE IN COPENHAGEN & ONLINE

ANNUAL ESTRO CONGRESS

WWW.ESTRO.ORG

Michelle LEECH (IRELAND)

ESTRO2022

Vote Ask a question

ESTRO2022 6-10 May 2022
Copenhagen, Denmark

AIRO2023


AI in the RT workflow

Radioterapia Oncologica:
l'evoluzione al servizio dei pazienti

Summary

Many roles for AI in the RT workflow

- AI algorithms are applicable to almost all aspects of the RT workflow
- Commercial solutions are now available
- Segmentation is one of the most visible applications
- Pseudo CT software is also making its way into the clinic
- Some aspects will naturally remain research topics





UAB Radiation Oncology
@UABRadonc

Congrats to our @UABmedphys #KillingCancerWithCode team who won 1st place at the @ESTRO_RT 2023 Auto-RTP Challenge. 13 international teams from academia and industry participated in the competition, all leveraging #AI and software tools to fully automate #RT treatment planning


[Traduci post](#)



UTSW Radiation Oncology
@UTSW_RadOnc

This is made possible by AI-guided diagnostics MRI to synthetic CT generation, surface image guidance setup, and Ethos online adaptive therapy. This treatment is traditionally complicated and takes days to plan. Now with AI and Ethos, we can do day 0 immediate treatment!

[Traduci post](#)



O'Neil et al. *BMC Palliative Care* (2022) 21:220
<https://doi.org/10.1186/s12904-022-01115-y>

BMC Palliative Care

STUDY PROTOCOL

Open Access

DART: diagnostic-CT-enabled planning: a randomized trial in palliative radiation therapy (study protocol)



Melissa O'Neil, Timothy K. Nguyen, Joanna Laba, Robert Dinniwel, Andrew Warner and David A. Palma*




Diagnostic-CT-Enabled Planning: A Randomized Trial in Palliative Radiation Therapy

Palliative patients with bone/soft tissue/lung disease in thorax/abdo/pelvis who meet eligibility criteria and consent to participate
 n=33


Randomization
1:2

Arm 1: CT simulation planning
(Conventional workflow)

Arm 2: Diagnostic-CT-enabled
planning (dCT)
(Experimental workflow)



Results: Primary Endpoint (TIC)



Time in centre (hrs)	Arm 1	Arm 2
Median (IQR)	4.8 (3.8, 5.8)	0.4 (0.3, 0.5)
Mean \pm SD	4.7 \pm 1.1	0.4 \pm 0.1

$p < 0.001$

London Health Sciences Centre

#ASTRO23



Melissa O'Neil MRT(T)

@Melissa_O_Neil

So excited to present DART RCT at the #ASTRO2023 late-breaking abstract and press sessions

Diagnostic CT-based planning pt time at cancer center from almost 5hrs to <0.5hrs w/out detriment to plan quality

Pts reported time burden

Do you ? Join our Delphi study!

Impact of AI on Quality of Care, Clinical Practice and Training

- Variation in quality exists, but regionalization is NOT the solution;
 - AI can reduce unrewarding tasks that consume time/cognitive burden;
 - AI can also inform or facilitate strategies to enhance quality (simulation training for complex cases, patient selection for escalation of clinical care);
- **There will be pluses and minuses, but change is certain;**
- **Success will come through networking within us and across disciplines;**



Erin Gillespie



Deep learning in digital histopathology for prostate cancer

- AI derived prognostic biomarkers provide personalized risk estimates, that when grouped allows more streamlined communication;
- ArteraAI MMAI prognostic tool identifies 6-fold more low-risk patients than NCCN (safe omitting of ADT with RT, with a NNT>25);
- **Prognostic biomarkers help with shared-decision making to avoid futile treatment intensification;**
- **Use of AI tools leveraging digital pathology improves prognostication, enabling us to determine the optimal treatment plan for the single patient (precision medicine);**




Jonathan Tward



Current Progress of Machine Learning in Radiation Oncology


Please tell me how concerned you are about the use of AI in medicine for each of the following:

1. That my health information will be kept confidential
2. That AI will make the wrong diagnosis
3. That AI will mean I spend less time with my doctor
4. That AI will increase my healthcare costs



For each of the following, please tell me how comfortable you would feel with AI doing some of the things your doctor usually does:

1. Reading your chest x-ray
2. Diagnosing pneumonia
3. Telling you that you have pneumonia
4. Recommending your antibiotic
5. Diagnosing cancer
6. Telling you that you have cancer



Sanjay Aneja



Radiography 29 (2023) S112–S116


Contents lists available at [ScienceDirect](#)

Radiography

journal homepage: www.elsevier.com/locate/radi



ELSEVIER



Patient views on the implementation of artificial intelligence in radiotherapy

S. Temple*, C. Rowbottom, J. Simpson

The Clatterbridge Cancer Centre NHS Foundation Trust, 65 Pembroke Place, Liverpool L7 8YA, UK



Overall, there was a moderately negative patient view towards the use of AI in radiotherapy.

Certain factors drew a more negative response than others, for example **patients desire significant personal interaction with healthcare professionals during the course of their treatment.**

No correlations with age and gender.

AIRO2023

Exploring ethical challenges in RadOnc AI

Radioterapia Oncologica:
l'evoluzione al servizio dei pazienti

- While waivers can be ethical and pragmatic solutions, patients have no idea that AI is being used in research or care involving them;
- **If for minimal risk for quality systems we can rely on good ML practice, for higher risk we necessitate prospective informed consent!**
- Umbrella consent needed to inform patients;
- **Additional disclosure duties: patient access to information about specific AI algorithms used in their care;**



Subha Perni


Conditions	Study Titles	NCT Numbers	Interventions
Lung Cancer	MIRA Clinical Learning Environment (MIRACLE): Lung	NCT05689437	Various machine learning models for ILD prediction, SGR prediction, and lung density monitoring
Early Stage Non-small Cell Lung Cancer, Non-small Cell Lung Cancer	Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR) for the Treatment of Central and Ultra-Central Early-Stage Non-Small Cell Lung Cancer	NCT05785845	Computed tomography-guided stereotactic adaptive radiotherapy, ETHOS device
Various heart-related conditions	Stress Echo 2030: the Novel ABCDE-(FGLPR) Protocol to Define the Future of Imaging	NCT05081115	Various diagnostic tests related to stress echo
Breast Cancer, Axillary Lymph Node Dissection, Breast Cancer Related Lymphedema, Axillary Reverse Mapping	Nomogram to Predict Breast Cancer Related Lymphedema	NCT04665882	Axillary surgery based on lymphedema prediction nomogram
Esophageal Neoplasm	Response Prediction to Neoadjuvant Chemoradiation in Esophageal Cancer Using Artificial Intelligence & Machine Learning	NCT04489368	Neo-Adjuvant Radiotherapy, Neo-Adjuvant Chemotherapy, Esophagectomy
Metastasis to Liver, Colorectal Cancer	Comparison of Image Quality Between "Double Low Dose" Liver CT	NCT05790590	Double low dose CT, Standard dose CT
Various cancers (Prostate, Glioblastoma, Head and Neck, Kidney, Cervix)	MRI Guided Radiotherapy and Radiobiological Data: the ISRAR Database	NCT06041555	3 MRI sequences

Conditions	Study Titles	NCT Numbers	Interventions
Various Cancers (Arrhythmias, Cardiac, Breast, Prostate, Brain, Kidney, Head and Neck, Liver, Pancreatic, Spinal)	LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology	NCT05184790	-
Head and Neck Cancer	AI for Head Neck Cancer Treated With Adaptive RadioTherapy (RadiomicART)	NCT05081531	Adaptive Radiotherapy
Lung Carcinoma	Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study	NCT05802186	Various imaging and radiation procedures
Lung Cancer	Artificial Intelligence for Gross Tumour vOluMe Segmentation	NCT05775068	Radiotherapy
Pelvic Cancer	Post Radiotherapy MRI Based AI System to Predict Radiation Proctitis for Pelvic Cancers	NCT04918992	Artificial Intelligence

43 studies found in
ClinicalTrials.gov

PRO-React: Enhancing Cancer Patient Care

Study Design

Go to 

Study Type ⓘ : Observational [Patient Registry]

Estimated Enrollment ⓘ : 166000 participants

Observational Model: Cohort

Time Perspective: Prospective

Target Follow-Up Duration: 6 Months

Official Title: Development of an Artificial Intelligence-based Incident Prediction Algorithm to Improve Cancer Patient Care and Patient Safety

Actual Study Start Date ⓘ : August 3, 2022

Estimated Primary Completion Date ⓘ : December 2025

Estimated Study Completion Date ⓘ : December 2025

•Early Incident Prediction

- PRO-React predicts incidents early, reducing risks.

•Resource Optimization

- Identifying "low-risk" cases optimizes resource use.

•OMCAT Register

- Combines PRO data for accurate predictions.


•PRO Time Series Benefit

- High-frequency PRO data reduces delays.

Big Data Initiative: **Optimizing Data That is AI-Driven for Patient Treatments**

- AI mining of information from the patients through biopsies, blood examples, imaging;
- measuring biological prognostic changes along the way;
- exploring a mosaic of information;
- defining hypotheses in reaction to mechanistic understanding;

Three Attractions to PULSAR



*Robert Timmerman, M.D.
Professor and Department Chair*





Illustration by Townsend Majors.

Outline

- *Definition;*
- *Application in RadOnc;*
- *New application (ESTRO, ASTRO);*
- *Reaction of our community*
- *Is there a future for #RadOnc with AI?*



AIRO2023

Radioterapia Oncologica:
l'evoluzione al servizio dei pazienti

Genomic analysis in oncology with AI: the opportunity for RADONC

original reports




Drew Moghanaki @DrewMoghanaki · 16h

In risposta a @theabzlab

Congratulations on pushing us into the future.

I noticed a very high event rate in your cohort, suggesting these data will need to be validated in a healthier cohort to be applicable to operable pts.



ts in the other lung or pleura
ory were excluded from univar
ultivariate analyses because o
w sample size and variability in
ogic subtypes. Local failure wa
d as radiographic progression
1 cm of the planning target
e to maintain a consistent
ion of local/marginal failure in
l trials of SBRT.^{1,13,14} Prescripti

1 153 1



Drew Moghanaki @DrewMoghanaki · 16h

In risposta a @DrewMoghanaki e @theabzlab

This is a MUST READ paper for anyone coding local failures after SBRT. It shows how easy, but not how often, it is for coders to be fooled and overall LF. [doi.org/10.1016/j.ijro...](https://doi.org/10.1016/j.ijro)

Incidence of High-Risk Radiologic Features in Patients Without Local Recurrence After Stereotactic Ablative Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer

Ronden, BSc,¹ J.R. van Sörnsen de Koste, PhD,² C. Johnson, BSc,¹ Slotman, MD, PhD,¹ F.O.B. Spoelstra, MD, PhD,¹ Haasbeek, MD, PhD,¹ G. Blom, MD,¹ E.M. Bongers, MD,¹ Arner, MSc,¹ A. Ward, PhD, D. Palma, MD, PhD, FRCP,¹ Senan, MRCP, FRCR, PhD¹

¹Department of Radiation Oncology, VU Medical Center, Amsterdam, The Netherlands; ²London School of Cancer Program, London Health Sciences Centre, London, Ontario, Canada; ³Department of Oncology and Medical Biophysics, University of Western Ontario, London, Ontario, Canada

8 Jun 2017, and in revised form Sep 11, 2017. Accepted for publication Sep 14, 2017.

Summary


Stereotactic ablative radiation therapy (SBRT) for early-stage non-small cell lung cancer (NSCLC) is difficult to distinguish from tumor recurrence. All intent-to-treat patients (ITT) were reviewed at a workstation using an add-on tool for ChaiCing (Maptek Medical). Five clinicians who were blinded to clinical outcomes or presence of HRFs: enlarging opacity (EO), sequential enlarging opacity, or enlarging opacity after 12 months (EO12), helping margin, loss of linear margins, cranial growth, and loss of air bronchogram. After each review, clinicians needed follow-up procedures based on published recommendations.

Results: A total of 88 patients (747 CT scans) were evaluated. The top 8 most frequently recorded by ≥3 observers on at least 1 follow-up scan were EO


Purpose:

To investigate, in the setting of stereotactic ablative radiation (SBRT) for early-stage non-small cell lung cancer, the incidence and pattern change in high-risk radiologic features (HRFs) in patients known to have no local recurrence. **Methods and Materials:** Computed tomography (CT) scans of patients treated with SBRT between 2008 and 2013 were available for 2 years and no local recurrences were identified. All scans were reviewed at a workstation using an add-on tool for ChaiCing (Maptek Medical). Five clinicians who were blinded to clinical outcomes or presence of HRFs: enlarging opacity (EO), sequential enlarging opacity, or enlarging opacity after 12 months (EO12), helping margin, loss of linear margins, cranial growth, and loss of air bronchogram. After each review, clinicians needed follow-up procedures based on published recommendations.

Results: A total of 88 patients (747 CT scans) were evaluated. The top 8 most frequently recorded by ≥3 observers on at least 1 follow-up scan were EO



Ronden et al. International Journal of Radiation Oncology • Biology • Physics




Cumulative mean incidence rates of each high-risk radiologic feature (HRF) by follow-up category, based on 88 patients and 747 CT scans for (A) percentage of total scans with overall incidence rates of any HRF, and (B) percentage of total scans with overall incidence rates of any HRF. Abbreviations: BM = helping margin; cranio-caudal growth; EO = enlarging opacity; EO12 = enlarging opacity after 12 months; LOB = loss of linear margin; LOM = loss of linear margin; SE = sequential enlarging opacity.

1 1 107

AIRO2023

Radioterapia Oncologica:
l'evoluzione al servizio dei pazienti

Things to remember: AI performance depends on the TRAINING



Don't try to get AI to replace the expert!



available at www.sciencedirect.com
journal homepage: euoncology.europeanurology.com



Digital Rectal Examination Is Not a Useful Screening Test for Prostate Cancer



Todd Scarbrough
@toddscarbrough

Blowing raspberries in radiologists' (replace a single iota of anything we exams)

Agne Krilaviciute^{a,†}, Nikolaus Becker^{a,†}, Jale Lakes^b, Jan Philipp Radtke^b, Markus Kuczyk^c, Inga Peters^{c,‡}, Nina N. Harke^c, Jürgen Debus^{d,e}, Stefan A. Koerber^d, Kathleen Herkommer^f, Jürgen E. Gschwend^f, Valentin H. Meissner^f, Axel Benner^g, Petra Seibold^a, Glen Kristiansen^h, Boris Hadaschik^{ij}, Christian Arsov^{b,§}, Lars Schimmöller^k, Frederik Lars Giesel^l, Gerald Antoch^k, Marcus Makowski^m, Frank Wackerⁿ, Heinz-Peter Schlemmer^o, Rudolf Kaaks^{p,ll}, Peter Albers^{a,b,ll,*}

Radiotherapy and Oncology 186 (2023) 109747

Contents lists available at [ScienceDirect](https://www.sciencedirect.com)

Radiotherapy and Oncology

journal homepage: www.thegreenjournal.com



ELSEVIER



Original Article

An investigation into the risk of population bias in deep learning autocontouring

Yasmin McQuinlan^a, Charlotte L. Brouwer^{b,*}, Zhixiong Lin^c, Yong Gan^c, Jin Sung Kim^d, Wouter van Elmpt^e, Mark J. Gooding^{f,g}




Mark Gooding

@SciChief

Is your [#AI](#) [#autocontouring](#) for [#RadOnc](#) racist?

It might be reasonable to assume we are all the same on the inside, but could bias inherent in a training set from one demographic impact performance in another?

observer ■ China ■ Netherlands ■ South Korea





William A Hall, MD


@whallradonc

Two ways to look at AI: Fear or Excitement?

1. I want my oncological modalities to be perfect, no failures, no toxicity;
2. I would like to have predictive models to educate patients as to their outcomes from specific therapies;
3. AI tools will only replace doctors who don't use them with doctors that do!

Outline

- *Definition;*
 - *Application in RadOnc;*
 - *New application (ESTRO, ASTRO);*
 - *Reaction of our community*
- *Is there a future for #RadOnc with AI?*



Where were we until 20 years ago?



3DRT



IMRT



VMAT



MRI-LINAC



SRT




?

What is happening now?

La radiologia medica (2023) 128:252-260
<https://doi.org/10.1007/s11547-022-01586-2>

SOAP Applicant Characteristics

- From 2014-2023:
 - 7% (132/1,952) of all RO residency positions were filled via the SOAP
- Of these 132 SOAP applicants:
 - **91% were filled from 2019-2023**
 - 73% were United States (US) MD seniors
 - 17% were US MD graduates
 - 11% were other graduates (US IMGs, US DO Grads, IMGs, US DO Seniors)
- Since 2019, at **roughly 76% (88/116)** of RO positions filled in the SOAP were accepted by applicants who did not list an RO program in their initial NRMP Certified Rank List




Slide courtesy of ARRO
Kelsey Corrigan MD, MPH

@ChelseaPinnix

ASTRO 65TH ANNUAL MEETING | October 1-4, 2023 #ASTRO23


Applications received per position, by specialty
NRMP Match®, 2022



Adapted from 2022 NRMP Program Director Survey



@jbcarmody





AIRO2023

Radioterapia Oncologica:
l'evoluzione al servizio dei pazienti



Where will we be in 10 years?



Conclusions

- In the next years we will see many different application of AI in RadOnc workflow;
- Current applications focus on contouring, planning, adaptive;
- Future development in other areas (genomic profiling, radiomics) could have an high impact on RadOnc;
- Ethical challenges need to be solved;
- A big effort of RadOnc community is needed to integrate AI and build a solid future for our community!



There is no SOUL in
the MACHINE.
Only in front of it.



Without you, it's just DATA.

Thank you!

